Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. Here, CD22 is linked to B-cell non-Hodgkin lymphoma.